Corruption Allegations Surround Western Laboratories, Including France's Sanofi, Over Drug Deals in Russia

An investigative report conducted by the outlet 'Proekt' in collaboration with the International Consortium of Investigative Journalists (ICIJ) and the Swiss platform 'Republik' has exposed details of a massive corruption network that squanders nearly half a billion dollars annually on imported pharmaceutical procurement in Russia, involving prominent international pharmaceutical laboratories, notably the French giant 'Sanofi'.

Shocking Figures and Systematic Kickbacks

The eleven-month investigation, covered by French media outlets including 'Courrier International', was based on documents and testimony from a pharmaceutical executive identified as 'Antonina'. According to the investigation, sales by eight Swiss, British, American, French, and Japanese pharmaceutical laboratories to the Russian public sector are estimated at approximately 386 billion rubles (equivalent to 4.2 billion euros).

Estimates indicate that between 10 and 20 percent of the value of each public contract for expensive and complex drugs is allocated to paying bribes to doctors, department heads, government officials, and security service personnel. Calculating the lower end of this estimate reveals that at least 38.5 billion rubles (nearly 420 million euros) are funneled annually to fuel this corrupt system.

Western Laboratories at the Heart of the System

The witness explained that Western laboratories incorporate these amounts into their sales forecasts from the outset, while local intermediaries and distributors handle the actual payments on the ground. The Swiss group 'Roche' ranks as the leading foreign supplier to the Russian public sector, while France's 'Sanofi' holds fourth place.

This scheme primarily targets cancer treatments, which represent more than 40 percent of state pharmaceutical purchases. Sources confirmed that Western companies grant Russian distributors substantial commercial bonuses ranging between 30 and 60 percent of the package price, to be used in funding what is termed 'procurement accompaniment'—a promotional euphemism for influencing decision-makers and safeguarding the progress of deals.

Humanitarian Repercussions and Intertwined Interests

The findings emphasize that patients pay the ultimate price, as the prices of these medications could have been 15 to 25 percent lower were it not for these illicit practices. Meanwhile, the investigations point to prominent businessmen profiting, most notably Alexey Repik and Viktor Kharitonin, alongside overlapping interests with influential figures close to the authorities and the circle of Chechen President Ramzan Kadyrov, though no direct link to bribery has been proven against them.

It is noted that the death of Russian opposition figure Alexei Navalny on February 16, 2024, was the primary motivation for the whistleblower to break her silence and hand over documents to the independent press, in hopes of exposing violations that adversely affect the lives of thousands of patients battling intractable diseases.